INTERCEPT Blood System
The INTERCEPT Blood System, pathogen reduction system, a proactive approach to TTI risk reduction provides continued protection against TTIs through broad spectrum inactivation of viruses, bacteria, and parasites. INTERCEPT is approved as an alternative to gamma irradiation for prevention of transfusion-associated graft versus host disease (TA-GVHD) in platelet components.
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
A quality product
Reducing pathogens in platelet units
System inactivates a wide range of bacteria and viruses - a quality product
Review Date: 11 Jan 2019 | Cerus
Safe donated blood is critical to improving certain patient outcomes. Transfusion-transmitted infectious (TTI) risk has greatly reduced due to current testing measures; yet, residual risks exist such as those due to emerging pathogens and bacterial contamination.
The INTERCEPT Blood System, pathogen reduction system, a proactive approach to TTI risk reduction provides continued protection against TTIs through broad spectrum inactivation of viruses, bacteria, and parasites. INTERCEPT is approved as an alternative to gamma irradiation for prevention of transfusion-associated graft versus host disease (TA-GVHD) in platelet components.
Recognized as a safe, effective and reliable choice of European blood centers for over a decade, INTERCEPT is now FDA approved, bringing the proven benefits of pathogen inactivation by reduction to the US.
